- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Arvinas Announces Chief Financial Officer Transition
- Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
- Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
- Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
- Arvinas Appoints Jared Freedberg as General Counsel
- Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
More ▼
Key statistics
On Wednesday, Arvinas Inc (ARVN:NSQ) closed at 33.45, -36.98% below its 52-week high of 53.08, set on Feb 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.73 |
---|---|
High | 33.91 |
Low | 32.80 |
Bid | 22.65 |
Offer | 39.00 |
Previous close | 33.45 |
Average volume | 594.30k |
---|---|
Shares outstanding | 68.08m |
Free float | 65.76m |
P/E (TTM) | -- |
Market cap | 2.28bn USD |
EPS (TTM) | -6.62 USD |
Data delayed at least 15 minutes, as of Apr 17 2024 21:00 BST.
More ▼